Scientific article

Efalizumab in the treatment of psoriasis

Published inBiologics, vol. 1, no. 3, p. 301-309
Publication date2007

The humanized antibody efalizumab is currently the only T-cell directed biologic approved for the treatment of moderate-to-severe psoriasis by both American and European authorities. Binding to and blocking the function of the adhesion molecule leukocyte function associated antigen 1 (LFA-1), it is believed to interfere with T-cell activation in the lymph node, migration through the circulation into the skin, and re-activation in-loco, all of these representing central steps in the pathogenesis of psoriasis. A comprehensive clinical development program provided large and consistent evidence that efalizumab induces a major clinical benefit in psoriasis. Efalizumab rapidly and substantially improves psoriatic skin symptoms and leads to profound gain in quality of life. It allows safe and effective long-term control of psoriasis. Therefore, evidence-based treatment guidelines recommend its use in moderate to severe plaque-type psoriasis.

Affiliation Not a UNIGE publication
Citation (ISO format)
BOEHNCKE, Wolf-Henning. Efalizumab in the treatment of psoriasis. In: Biologics, 2007, vol. 1, n° 3, p. 301–309.
Main files (1)
ISSN of the journal1177-5475

Technical informations

Creation09/20/2013 4:48:47 PM
First validation09/20/2013 4:48:47 PM
Update time03/14/2023 8:25:53 PM
Status update03/14/2023 8:25:53 PM
Last indexation02/12/2024 8:33:24 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack